{"id":31511,"date":"2025-04-10T11:52:50","date_gmt":"2025-04-10T03:52:50","guid":{"rendered":"https:\/\/flcube.com\/?p=31511"},"modified":"2025-04-10T11:52:51","modified_gmt":"2025-04-10T03:52:51","slug":"sinopep-allsino-partners-with-gulf-pharmaceutical-for-semaglutide-api-supply","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31511","title":{"rendered":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply"},"content":{"rendered":"\n

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076<\/a>) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.<\/p>\n\n\n\n

Partnership Details<\/strong>
Sinopep-Allsino will provide Julphar with comprehensive support, including necessary documents and information for quality research and regulatory filing. The agreement also encompasses on-site technology transfer and technical assistance to address any technical challenges that may arise during the registration or production processes.<\/p>\n\n\n\n

Market Expansion<\/strong>
This strategic partnership positions Sinopep-Allsino to leverage Julphar\u2019s established commercial network in the region, facilitating entry into the promising MEA market. The collaboration underscores Sinopep-Allsino’s commitment to expanding its global presence and supporting regional pharmaceutical development through innovative solutions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed…<\/p>\n","protected":false},"author":1,"featured_media":31515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,86,2668,2561],"class_list":["post-31511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-diabetes","tag-obesity","tag-sha-688076","tag-sinopep-allsino-biopharmaceutical"],"yoast_head":"\nSinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31511\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply\" \/>\n<meta property=\"og:description\" content=\"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31511\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T03:52:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T03:52:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply\",\"datePublished\":\"2025-04-10T03:52:50+00:00\",\"dateModified\":\"2025-04-10T03:52:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511\"},\"wordCount\":154,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1001-png.webp\",\"keywords\":[\"Diabetes\",\"Obesity\",\"SHA: 688076\",\"Sinopep-Allsino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31511#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31511\",\"name\":\"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1001-png.webp\",\"datePublished\":\"2025-04-10T03:52:50+00:00\",\"dateModified\":\"2025-04-10T03:52:51+00:00\",\"description\":\"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31511\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1001-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1001-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31511#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply - Insight, China's Pharmaceutical Industry","description":"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31511","og_locale":"en_US","og_type":"article","og_title":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply","og_description":"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.","og_url":"https:\/\/flcube.com\/?p=31511","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-10T03:52:50+00:00","article_modified_time":"2025-04-10T03:52:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31511#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31511"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply","datePublished":"2025-04-10T03:52:50+00:00","dateModified":"2025-04-10T03:52:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31511"},"wordCount":154,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31511#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","keywords":["Diabetes","Obesity","SHA: 688076","Sinopep-Allsino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31511#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31511","url":"https:\/\/flcube.com\/?p=31511","name":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31511#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31511#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","datePublished":"2025-04-10T03:52:50+00:00","dateModified":"2025-04-10T03:52:51+00:00","description":"Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed a supply agreement with Gulf Pharmaceutical Industries, a UAE-based pharmaceutical company, for its semaglutide active pharmaceutical ingredients (APIs). This collaboration covers 22 countries in the Middle East and Africa (MEA), including the United Arab Emirates, Qatar, Saudi Arabia, Egypt, and Morocco.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31511#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31511"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31511#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","width":1080,"height":608,"caption":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31511#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1001-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31511"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31511\/revisions"}],"predecessor-version":[{"id":31512,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31511\/revisions\/31512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31515"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}